Linked Life Data

15107935

Source:http://linkedlifedata.com/resource/pubmed/id/15107935

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2004-4-26
pubmed:abstractText
The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as front-line therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5%) achieved complete remission and 4 (4.3%) partial remission. Three patients (3.2%) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9%, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0100-879X
pubmed:author
pubmed:issnType
Print
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
719-28
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:15107935-Adolescent, pubmed-meshheading:15107935-Adult, pubmed-meshheading:15107935-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:15107935-Bleomycin, pubmed-meshheading:15107935-Cyclophosphamide, pubmed-meshheading:15107935-Doxorubicin, pubmed-meshheading:15107935-Etoposide, pubmed-meshheading:15107935-Female, pubmed-meshheading:15107935-Humans, pubmed-meshheading:15107935-Italy, pubmed-meshheading:15107935-Lymphoma, Non-Hodgkin, pubmed-meshheading:15107935-Male, pubmed-meshheading:15107935-Middle Aged, pubmed-meshheading:15107935-Neoplasm Staging, pubmed-meshheading:15107935-Prednisone, pubmed-meshheading:15107935-Prospective Studies, pubmed-meshheading:15107935-Radiotherapy, Adjuvant, pubmed-meshheading:15107935-Survival Analysis, pubmed-meshheading:15107935-Treatment Outcome, pubmed-meshheading:15107935-Vincristine
pubmed:year
2004
pubmed:articleTitle
A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
pubmed:affiliation
Department of Hematology, San Martino Hospital, Genoa, Italy. gino.santini@hsanmartino.liguria.it
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study